Reviva Pharmaceuticals Holdings, Inc. (RVPH)
| Market Cap | 13.06M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -18.67M |
| Shares Out | 18.13M |
| EPS (ttm) | -0.87 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 285,945 |
| Open | 0.729 |
| Previous Close | 0.728 |
| Day's Range | 0.700 - 0.750 |
| 52-Week Range | 0.530 - 4.660 |
| Beta | 0.18 |
| Analysts | Buy |
| Price Target | 9.86 (+1,269.4%) |
| Earnings Date | Aug 15, 2022 |
About RVPH
Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is RP5063, which is in Phase III clinical trials for the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attention"deficit/hyperacti... [Read more...]
Financial Performance
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for RVPH stock is "Buy." The 12-month stock price forecast is 9.86, which is an increase of 1,269.44% from the latest price.
News
Reviva Pharmaceuticals Holdings, Inc. Reports Second Quarter 2022 Financial Results and Recent Business Highlights
- Enrollment on pace for ongoing pivotal Phase 3 RECOVER trial -
Reviva Pharmaceuticals Provides Update on Clinical Development Pipeline
Enrollment remains on pace for Reviva's Phase 3 clinical trial for the treatment of schizophrenia at 15 sites across the US with enrollment set to begin at sites in Europe and India in Q3 2022
Reviva Pharmaceuticals to Participate in the 2022 BIO International Convention
CUPERTINO, Calif.,, June 02, 2022 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that ...
Reviva Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference
CUPERTINO, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that se...
Reviva Pharmaceuticals Holdings, Inc. Reports First Quarter 2022 Financial Results and Recent Business Highlights
- Hosted key opinion leader (KOL) webinar on brilaroxazine for schizophrenia and other neuropsychiatric disorders led by industry thought leaders Leslie Citrome, MD & Larry Ereshefsky, PharmD
Reviva Pharmaceuticals Announces Update on RECOVER, a Pivotal Phase 3 Global Study Evaluating Brilaroxazine for the T...
CUPERTINO, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that se...
Reviva Pharmaceuticals Holdings, Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report®
CUPERTINO, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH), (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that...
Reviva Pharmaceuticals Holdings, Inc. to Participate at the Maxim Virtual Growth Conference
CUPERTINO, Calif., March 22, 2022 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that ...
Reviva Pharmaceuticals Holdings, Inc. to Present at Upcoming Virtual Investor Conferences
- 5 th Annual Neuroscience Innovation Forum -
Reviva Pharmaceuticals Holdings, Inc. Reports Full Year 2021 Financial Results and Recent Business Highlights
- Topline data for pivotal Phase 3 trial evaluating brilaroxazine for the treatment of schizophrenia anticipated in mid-2023
Reviva Pharmaceuticals Announces First Patients Dosed in Pivotal Phase 3 Study and Long-Term Safety Trial Evaluating ...
- RECOVER is a Phase 3, randomized, double-blind study with registrational intent -
FDA Gives Green Signal To Reviva Pharma's Late-Stage Schizophrenia Trial
The FDA has notified Reviva Pharmaceuticals Holdings Inc (NASDAQ: RVPH) that it may proceed with Phase 3 trial of its lead candidate, brilaroxazine, a serotonin and dopamine receptor modulator for schiz...
Reviva Pharmaceuticals Holdings, Inc. Receives FDA May Proceed Letter for Pivotal Phase 3 Clinical Trial and Long-Ter...
- Brilaroxazine is a novel serotonin and dopamine receptor modulator currently being developed for diseases with dysfunctional serotonin signaling including neuropsychiatric and pulmonary indications -
Reviva Pharmaceuticals to Participate in the Upcoming January Virtual Investor Conferences
CUPERTINO, Calif., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that s...
Reviva Pharmaceuticals Holdings, Inc. Reports Third Quarter 2021 Financial Results and Recent Business Highlights
- Initiation of a pivotal Phase 3 trial evaluating the efficacy and safety of brilaroxazine for the treatment of schizophrenia expected by year-end -
Reviva Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
CUPERTINO, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that ...
Reviva Pharmaceuticals Holdings, Inc. Reports Second Quarter 2021 Financial Results and Recent Business Highlights
-Closed Underwritten Public Offering of Common Stock and Warrants Resulting in Gross Proceeds of $34.5 Million
Reviva Pharma Stock Is Trading Higher After Maxim Initiated With Buy, Target Price Of $10
Reviva Pharmaceuticals Holdings Inc (NASDAQ: RVPH) is trading higher with around 60k in session volume. Maxim initiated coverage of Reviva with a Buy rating and $10 price target, equivalent to an upside...
Reviva Added to Russell Microcap® Index
CUPERTINO, Calif., June 28, 2021 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (along with its subsidiaries, “Reviva” or the “Company”), a clinical-stage pharmaceutical compan...
Reviva Announces Pricing of Upsized $30 Million Underwritten Public Offering
CUPERTINO, Calif., May 26, 2021 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that se...
RVPH Stock: Why Reviva Pharmaceuticals Is Skyrocketing 90% on Monday
Today, investors in RVPH stock saw some pretty massive gains, as the company announced impressive results for its schizophrenia drug. The post RVPH Stock: Why Reviva Pharmaceuticals Is Skyrocketing 90% ...
Why Voyager Therapeutics, uniQure, Axsome, Reviva Pharma and Crispr Are Moving Today
Voyager Therapeutics, Inc. (NASDAQ: VYGR), uniQure N.V. (NASDAQ: QURE), Axsome Therapeutics, Inc. (NASDAQ: AXSM), Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) and CRISPR Therapeutics AG (NASDAQCR...
Here's why Reviva Pharmaceuticals soared more than 100% on Monday
Shares of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) more than doubled in value Monday after the clinical-stage biopharmaceutical company reported encouraging phase 2 clinical trial results fo...
Reviva's stock jumps after experimental schizophrenia drug meets endpoint in Phase 2 clinical trial
Shares of Reviva Pharmaceuticals Holdings Inc. soared 76.6% in trading on Monday after the company said its experimental treatment for schizophrenia met the primary endpoint in a mid-stage clinical tria...
Reviva Pharma Stock Trading Higher On Detailed Positive Schizophrenia Study Results
Reviva Pharmaceuticals Holdings Inc (NASDAQ: RVPH) has announced the full details of its Phase 2 trial evaluating its lead drug candidate, RP5063 (brilaroxazine), for Acute Schizophrenia. Brilaroxazine ...